A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients
| العنوان: | A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients |
|---|---|
| المؤلفون: | S. Caponi, Elisa Paolicchi, Daniela Campani, Pinuccia Faviana, Elisa Giovannetti, Godefridus J. Peters, Niccola Funel, Ugo Boggi, Amir Avan, Paola Pacetti, Enrico Vasile, Michele Reni, Mina Maftouh, Andrea Mambrini, Michele Milella, Vanja Vaccaro, Maurizio Cantore |
| المساهمون: | Medical oncology laboratory, CCA - Innovative therapy |
| المصدر: | Maftouh, M, Avan, A, Funel, N, Paolicchi, E, Vasile, E, Pacetti, P, Vaccaro, V, Faviana, P, Campani, D, Caponi, S, Mambrini, A, Boggi, U, Cantore, M, Milella, M, Peters, G J, Reni, M & Giovannetti, E 2014, ' A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients ', Pharmacogenomics, vol. 15, no. 5, pp. 609-618 . https://doi.org/10.2217/pgs.13.225Test Università di Pisa-IRIS Pharmacogenomics, 15(5), 609-618. Future Medicine Ltd. |
| بيانات النشر: | Future Medicine Ltd, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Male, Antimetabolites, Antineoplastic, Prognostic factor, Pancreatic ductal adenocarcinoma, Antimetabolites, Locally advanced, macromolecular substances, Deoxycytidine, Promoter Regions, Cohort Studies, Genetic, Pancreatic cancer, Genetics, medicine, Humans, SNP, Enhancer of Zeste Homolog 2 Protein, Polymorphism, Promoter Regions, Genetic, Aged, Pharmacology, Polymorphism, Genetic, business.industry, EZH2, Polycomb Repressive Complex 2, DNA, Middle Aged, medicine.disease, Antineoplastic, Survival Analysis, Gemcitabine, Pancreatic Neoplasms, MicroRNAs, Treatment Outcome, Cohort, Disease Progression, Cancer research, Molecular Medicine, Female, business, medicine.drug |
| الوصف: | Aim: EZH2 expression is a prognostic marker in radically resected pancreatic ductal adenocarcinoma (PDAC) patients. Here we investigated its role in locally advanced/metastatic patients, as well as candidate polymorphisms. Materials & methods: EZH2 expression and polymorphisms were evaluated by quantitative reverse transcription PCR in 32 laser microdissected tumors, while polymorphisms were also studied in blood samples from two additional cohorts treated with gemcitabine monotherapy (n = 93) or polychemotherapeutic regimens (n = 247). Results: EZH2 expression correlated with survival and with the rs6958683 polymorphism in the first cohort of patients, but this polymorphism was not associated with survival in our larger cohorts. Conclusion: EZH2 is a prognostic factor for locally advanced/metastatic PDACs, while candidate polymorphisms cannot predict clinical outcome. Other factors involved in EZH2 regulation, such as miR-101, should be investigated in accessible samples in order to improve the clinical management of advanced PDAC. Original submitted 31 July 2013; Revision submitted 4 November 2013 |
| تدمد: | 1744-8042 1462-2416 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bc8f783cd084710d92d4ab8ad3e724eTest https://doi.org/10.2217/pgs.13.225Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4bc8f783cd084710d92d4ab8ad3e724e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17448042 14622416 |
|---|